Investment Rating - The industry investment rating is "Outperform the Market" [1][22]. Core Insights - The report highlights that the liquor industry is experiencing a phase of accelerated clearing, with major companies like Kweichow Moutai showing resilience despite a slowdown in growth [1][4]. - The overall performance of the food and beverage sector has been mixed, with certain sub-sectors like pre-processed foods and snacks performing well, while soft drinks and other alcoholic beverages have seen declines [3][4]. - The report emphasizes the importance of focusing on high-quality companies with stable earnings during the industry's adjustment period, particularly recommending Kweichow Moutai and Shanxi Fenjiu for their strong fundamentals and attractive dividend yields [4]. Summary by Sections Liquor Industry - Kweichow Moutai reported Q3 2025 revenue of 39.064 billion yuan, a year-on-year increase of 0.56%, with net profit of 19.224 billion yuan, up 0.48% [3]. - The revenue from Moutai liquor increased by 7.26% to 34.924 billion yuan, while series liquor revenue fell by 34% [3]. - The company's gross margin improved to 91.44%, reflecting a better product mix, while net profit margin remained stable at 49.21% [3][4]. Dairy Industry - Yili Group's Q3 2025 revenue was 28.564 billion yuan, down 1.63%, with net profit of 3.226 billion yuan, a decrease of 3.35% [3]. - Liquid milk sales were under pressure, declining by 8.83%, while milk powder and dairy products saw a growth of 12.65% [3]. - The gross margin for Yili was 33.92%, down 1.13 percentage points, indicating cost pressures from raw milk prices [3]. Beauty Industry - Marubi Biotech achieved Q3 2025 revenue of 686 million yuan, up 14.28%, with net profit of 69 million yuan, an increase of 11.59% [4]. - The main brand Marubi saw a revenue increase of 33.93%, driven by strong performance of key products [4]. - The gross margin improved to 75.72%, supported by product mix optimization, despite increased marketing expenses [4].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 2.45 billion yuan for Q1-Q3 2025, representing a year-on-year increase of 25.51%, with a net profit of 244 million yuan, up 2.13% year-on-year [2] - The company continues to optimize its product structure, with strong performance from key products, particularly in the eye care and skincare categories [3] - The gross profit margin for Q1-Q3 2025 was 74.91%, showing a slight increase, while the net profit margin was 9.95%, reflecting a decrease [4] Revenue Summary - For Q3 2025, the company achieved a revenue of 686 million yuan, a year-on-year increase of 14.28% [2] - Breakdown of revenue by product category for Q3 2025: - Eye care: 149 million yuan (+20.10%) - Skincare: 306 million yuan (+42.05%) - Cleansing: 67 million yuan (+23.06%) - Beauty: 148 million yuan (-26.71%) - Other: 16 million yuan (+285.46%) [3] Profitability Summary - The company’s gross profit margin for Q3 2025 was 75.72%, an increase of 1.20 percentage points year-on-year [4] - The net profit margin for Q3 2025 was 10.13%, a slight decrease of 0.24 percentage points year-on-year [4] - The company plans to enhance cost control and stabilize expenses to improve profitability [5] Expense Summary - The operating expense ratio for Q1-Q3 2025 was 63.77%, an increase of 3.12 percentage points year-on-year [5] - For Q3 2025, the operating expense ratio rose to 69.04%, with increases in sales and management expenses attributed to heightened competition and increased team size [5] Investment Recommendations - The company is expected to achieve synchronized growth in revenue and profit due to brand strengthening and operational efficiency improvements [6] - Revised revenue forecasts for 2025-2027 are 3.68 billion, 4.48 billion, and 5.42 billion yuan respectively, with net profits of 397 million, 493 million, and 631 million yuan [6] - The estimated EPS for 2025-2027 is projected to be 0.99, 1.23, and 1.57 yuan, with corresponding PE ratios of 35, 28, and 22 times [6]